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Abstract
Background—Pulmonary hypertension (PHT) is reported to be associated with measures of
renal function in patients with sickle cell disease (SCD). The purpose of this exploratory study
was to determine the relationship between albuminuria and both clinical and laboratory variables
in SCD.
Design and Methods—This cross-sectional study was performed using a cohort of adult
patients with SCD and control subjects without SCD. Spot urine for microalbumin/creatinine ratio,
measures of hemolysis, inflammation and other laboratory studies were obtained. Pulmonary
artery systolic pressure was determined by Doppler echocardiography, and the diagnosis of PHT
was defined using age, sex and body mass index-adjusted reference ranges.
Results—73 patients with SCD and 21 healthy, race-matched control subjects were evaluated. In
patients with SCD, normoalbuminuria was observed in 34 patients (46.6%), microalbuminuria in
24 patients (32.9%) and macroalbuminuria in 15 patients (20.5%). There was a significant
correlation between urine albumin excretion and age. In HbSS and Sβ0 thalassemia patients, the
levels of sFLT-1, soluble VCAM and NT pro-BNP were significantly higher in those with
macroalbuminuria, compared to patients with microalbuminuria and normoalbuminura, but no
significant differences were observed in the levels of laboratory measures of hemolysis. Urine
albumin excretion was associated with PHT and a history of stroke.
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Conclusions—Our study confirms the high prevalence of albuminuria in SCD. The association
of urine albumin excretion with sFLT-1 suggests that this VEGFR family member may contribute
to the development of albuminuria in SCD. By inducing endothelial activation and endothelial
dysfunction, sFLT-1 appears to be a link between glomerulopathy and PHT in SCD.
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Introduction
Pulmonary hypertension (PHT) is a common complication in patients with sickle cell
disease (SCD) (1,2) and is associated with an increased risk of mortality in these patients
(1-4). While the pathogenesis of SCD-associated PHT is probably multifactorial, there is
evidence that chronic intravascular hemolysis, with subsequent destruction of nitric oxide by
cell-free plasma hemoglobin, plays a central role in this complication (1,5,6). More recently,
there have been numerous reports that suggest a role for inflammation in the
pathophysiology of SCD-associated PHT (7-11).
Albuminuria, a manifestation of glomerular injury, is also common in both children and
adults with SCD (12-14). Multiple studies report associations between various measures of
renal function and SCD-associated PHT (1,2,4), suggesting that both glomerulopathy and
PHT may share a similar pathophysiology in SCD.
The purpose of this exploratory study was to investigate the relationship between
albuminuria and clinical complications, as well as laboratory measures of hemolysis,
inflammation, and renal function in patients with SCD.
Design and Methods
Patients and Study Design
The patients evaluated in this cross-sectional study represent a cohort followed at the Adult
Sickle Cell Clinic at The University of North Carolina, Chapel Hill. The data were collected
as part of an ongoing study to investigate the pathophysiology of PHT in SCD. Consecutive
patients seen in clinic, as well as healthy, race-matched control subjects, who agreed to
participate in this study, were enrolled. Seventy-three patients with SCD were included in
the analyses that assessed the associations between urine albumin excretion (also referred to
as albuminuria) and other clinical and laboratory variables. Each enrolled patient was
studied while in the non-crisis, steady state; had not experienced an episode of acute chest
syndrome in the 4 weeks preceding enrollment; and had no clinical evidence of congestive
heart failure. No patient on chronic red cell transfusion was studied. All subjects gave
written informed consent to participate and the study was approved by the Institutional
Review Board.
All of the study evaluations were performed during the course of a single visit to the Clinical
and Translational Research Center. Urine albumin excretion was assessed by measuring spot
urine microalbumin/creatinine ratios. The urine albumin excretion, expressed as mg/ g
creatinine, was defined as normoalbuminuria (< 30 mg/ g creatinine), microalbuminuria (30
– 299 mg/ g creatinine) or macroalbuminuria (≥ 300 mg/ g creatinine) (12). Commercially
available ELISA kits (R&D Systems, Minneapolis, Minnesota) were used according to the
manufacturers' recommendations to measure levels of cystatin C, placenta growth factor
(PlGF), human soluble vascular cell adhesion molecule-1 (soluble VCAM-1), and soluble
fms-like tyrosine kinase 1 (sFLT-1). Measurements of N-terminal pro-brain natriuretic
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peptide (NT proBNP) and other routine laboratory studies were obtained in the clinical
laboratories at UNC Hospitals. Values of NT proBNP that were below the measurable limit
(<50 pg/dL) were assigned a value of 49 pg/dL, and values of urine microalbumin that were
below the measurable limit (0.6 mg/dL) were assigned a value of 0.5 mg/dL. The estimated
glomerular filtration rate (eGFR) was calculated using the abbreviated “Modification of Diet
in Renal Disease” (MDRD) study (GFR, in mL/min per 1.73 m2 = 186.3 × serum Cr
(exp[-1.154]) × Age (exp[- 0.203]) × (0.742 if female) × (1.21, if black) (15). The presence
of PHT was assessed by transthoracic Doppler echocardiography using a Hewlett-Packard
2500 Ultrasound System, with a 2·5/2·0 MHz ultrasound probe (Model 21215A) for
recording continuous wave signals. The pulmonary artery systolic pressure (PASP) was
calculated using the modified Bernoulli equation (PASP = 4V2 + right atrial pressure), with
the right atrial pressure assumed to be 10 mmHg (16). The diagnosis of PHT in our study
was based on adjusted PASP values for age, sex, and body mass index (16). The presence or
history of other clinical complications was ascertained from a history at the time of
evaluation, combined with a detailed review of the medical records.
Statistical Analysis
Albuminuria was analyzed as both a continuous and a trichotomized categorical variable.
We explored correlations between continuous covariates of interest using Spearman's Rank
Correlation Coefficient. When urine albumin excretion was categorized into normo-, micro-,
or macroalbuminuria, we used the Kruskal-Wallis method to test for significant differences
between the three categories and continuous covariates. Medians, with their distribution-free
95% confidence intervals, have been presented for these continuous covariates. Fisher's
exact tests were used to test for significant differences between this categorized urine
albumin excretion variable and categorical covariates of interest. All tests were two-sided (α
= 0.05). Reported p-values are considered ‘nominal’ and are for individual tests, unadjusted
for multiple comparisons because of the exploratory nature of this study. Statistical analyses
were performed using SAS software, version 9.2, SAS Institute, Cary, NC, USA.
Results
Demographics and Laboratory Characteristics
Seventy three subjects with SCD (SS = 61, SC = 8, Sβ0 = 3, Sβ+ = 1; 47 women) and 21
healthy, race-matched control subjects were evaluated in this study. The baseline
demographic and laboratory characteristics are shown in Table 1. Normoalbuminuria was
observed in 34 patients with SCD (46.6%), microalbuminuria in 24 patients with SCD
(32.9%) and macroalbuminuria in 15 patients with SCD (20.5%). There was a modest
correlation between age and albuminuria (r = 0.32, 95% CI: 0.09 – 0.51; p = 0.006),
although there was no significant difference when the ages of SCD patients with
macroalbuminuria, microalbuminuria and normoalbuminuria were compared (43 yrs vs. 40
yrs vs. 35 yrs; p = 0.12). There were no differences in the systolic and diastolic blood
pressures when patients with macroalbuminuria were compared to those with
microalbuminuria and normoalbuminuria. Although the level of lactate dehydrogenase
appeared to be higher in patients with macroalbuminuria compared to those with
microalbuminuria and normoalbuminuria (1136 U/L vs. 846 U/L vs. 773.5 U/L, p = 0.15),
there were no significant differences in the levels of chemical measures of hemolysis,
including both total and indirect bilirubin (Table 2). Patients with macroalbuminuria had
lower hemoglobin values compared with those patients with microalbuminuria and
normoalbuminuria (7.2 g/dL vs. 9.05 g/dL vs. 8.85 g/dL, p = 0.09), but this difference was
not statistically significant.
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As expected, the estimated glomerular filtration rate, assessed by the MDRD method was
lowest in patients with macroalbuminuria compared to patients with microalbuminuria and
normoalbuminuria (80.5 ml/min vs. 141.2 ml/min vs. 128.2 ml/min; p = 0.001).
Furthermore, the level of cystatin C was significantly higher in patients with
macroalbuminuria compared to other albuminuria categories (856.6 ng/mL vs. 565.5 ng/mL
vs. 494.7 ng/mL; p = 0.03).
When only those patients with sickle cell anemia (HbSS) and sickle β0 thalassemia (HbSβ0)
were evaluated, we observed similar results, with no significant differences in the levels of
lactate dehydrogenase (1175 U/L vs. 901 U/L vs. 914.5 U/L; p = 0.25), total bilirubin (2.3
mg/dL vs. 2.5 mg/dL vs. 1.9 mg/dL; p = 0.28) and indirect bilirubin (2.2 mg/dL vs. 2.3 mg/
dL vs. 1.8 mg/dL; p = 0.39) when patients with macroalbuminuria were compared to those
with both microalbuminuria and normoalbuminuria. However, patients with
macroalbuminuria had significantly lower hemoglobin values compared to those patients
with microalbuminuria and normoalbuminuria (7.1 g/dL vs. 9.1 g/dL vs. 8.7 g/dL, p =
0.033).
Association of Albuminuria with Biologic and Inflammatory Markers
There were no significant differences in the white blood cell counts (9.1 × 103/μL vs. 10.7 ×
103/μL vs. 8.75 × 103/μL; p = 0.08), absolute neutrophil counts (5.1 × 103/μL vs 5.25 × 103/
μL vs. 4.65 × 103/μL; p = 0.57) or absolute monocyte counts (0.60 × 103/μL vs 0.65 × 103/
μL vs. 0.40 × 103/μL; p = 0.11) when patients with macroalbuminuria were compared to
patients with microalbuminuria and normoalbuminuria (Table 2). NT-proBNP was
significantly higher in patients with macroalbuminuria compared with those patients with
microalbuminuria and normoalbuminuria (440 pg/mL vs. 68.5 pg/mL vs. 135 pg/mL; p =
0.01). The level of sFLT-1 was also significantly higher in patients with macroalbuminuria,
compared to patients with microalbuminuria and normoalbuminura (120.1 pg/mL vs. 99.7
pg/mL vs. 85.4 pg/mL; p = 0.016). Although the level of soluble VCAM-1 appeared to be
higher in patients with macroalbuminuria compared with patients with microalbuminuria
and normoalbuminura, the difference was not statistically significant (1337.9 ng/mL vs.
668.9 ng/mL vs. 753.4 ng/mL; p = 0.10). No significant difference in the level of PlGF was
observed in patients with macroalbuminuria, compared to patients with microalbuminuria
and normoalbuminura.
When only HbSS and HbSβ0 patients were evaluated, we observed no significant
differences in the white blood cell counts, absolute neutrophil counts or absolute monocyte
counts when patients with macroalbuminuria were compared to those with
microalbuminuria and normoalbuminuria. There were significantly higher levels of NT-
proBNP (593 pg/mL vs. 68.5 pg/mL vs. 135 pg/mL; p = 0.005), sFLT-1 (124.6 pg/mL vs.
99.7 pg/mL vs. 86.3 pg/mL; p = 0.035) and soluble VCAM-1 (1347 ng/mL vs. 765.4 ng/mL
vs. 753.4 ng/mL; p = 0.033) in patients with macroalbuminuria compared to those with
microalbuminuria and normoalbuminuria. No significant difference in the level of PlGF was
observed in patients with macroalbuminuria, compared to patients with microalbuminuria
and normoalbuminura.
Clinical Correlates of Albuminuria
In patients with measurable tricuspid regurgitant (TR) jet velocities, the TR jet velocities
were significantly higher in those with macroalbuminuria compared to patients with
microalbuminuria and normoalbuminuria (3.15 m/s vs. 2.45 m/s vs. 2.45 m/s; p = 0.00068).
We also observed significant associations between urine albumin excretion and both the
presence of PHT (p = 0.04) and a history of stroke (p = 0.002). No significant associations
were observed between urine albumin excretion and the number of acute pain episodes,
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history of acute chest syndrome, history of leg ulcers, history of priapism, retinopathy or
history of hypertension.
When only HbSS and HbSβ0 patients were evaluated, significant associations were observed
between urine albumin excretion and the presence of PHT (p = 0.046), stroke (p = 0.0018)
and history of hypertension (p = 0.021). We also observed trends towards association
between urine albumin excretion and use of hydroxyurea (p = 0.085) and presence of
retinopathy (p = 0.082).
Discussion
The increasing survival into adulthood of patients with SCD is associated with an increased
incidence of multi-organ dysfunction. Renal abnormalities are common in patients with
SCD. Like pulmonary hypertension, renal failure is a risk factor for death in SCD patients
(17). In our study of adult SCD patients, we observed that increased urine albumin excretion
is common, occurring in approximately 53% of patients. Approximately 33% of the study
patients had microalbuminuria, a value lower than the 42% prevalence reported by Guasch
and colleagues in a cohort of adult patients (12), but higher than the reported prevalence of
between 16% and 19% in children with SCD (13,14). The lower prevalence in children
compared with adults is consistent with our finding and that of others that albuminuria is
associated with increasing age (12-14,18).
Our finding that sFLT-1 is associated with urine albumin excretion, combined with data
associating sFLT-1 with albuminuria in other disease states suggests that sFLT-1 may play a
role in the development of albuminuria in SCD. The level of sFLT-1 is reported to be
elevated in SCD patients during the clinically asymptomatic state (19,20). sFLT-1 is a
member of the vascular endothelial growth factor receptor (VEGFR) family (21) and is a
splice variant of the VEGFR1. VEGF plays a critical role in glomerular development and
function, and is important in maintaining the glomerular filtration barrier. VEGF has also
been implicated in glomerular healing by facilitating glomerular capillary repair (22).
sFLT-1 lacks transmembrane and cytoplasmic domains, and acts by adhering to the
receptor-binding domains of VEGF and PlGF, preventing their interaction with endothelial
receptors on the cell surface and thereby inducing endothelial dysfunction. Significant
associations have been reported between serum levels of both sFLT-1 and VEGF with
urinary albumin excretion in normal pregnant women (22). High levels of sFLT-1 in the
serum and amniotic fluid of pregnant women, as well as excess placental sFLT-1 have been
found to contribute to endothelial dysfunction, hypertension and proteinuria in preeclampsia
by blocking the effects of VEGF and PlGF (23-25). Urinary and serum levels of VEGF and
sFLT-1 have also been reported to be significantly increased in microalbuminuric and
proteinuric patients with diabetes and essential hypertension, suggesting that VEGF and
sFLT-1 may play a role in the pathogenesis of the nephropathy associated with these
conditions (26,27). The association of urine albumin excretion with soluble VCAM in this
study, combined with the association of sFLT-1 with soluble VCAM (20) suggests that
sFLT-1 may contribute to the pathogenesis of albuminuria in SCD by promoting endothelial
activation and possibly, endothelial dysfunction.
Hemolysis appears to predispose SCD patients to a vasculopathy that may manifest as one
or more of several complications including PHT, leg ulceration, priapism, and possibly
stroke (28). Similar to a previous report by Guasch et al (12), we did not observe any
significant association between measures of hemolysis and albuminuria in our study. The
lower hemoglobin levels in our patients with macroalbuminuria compared to those with
microalbuminuria and normoalbuminuria is similar to the findings in previous reports that
showed associations of both albuminuria and proteinuria with lower hemoglobin
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(4,13,14,29). Although no significant associations between urine albumin excretion and
chemical markers of red cell destruction were observed in our relatively small study, the
level of lactate dehydrogenase was higher in patients with macroalbuminuria compared to
those with both microalbuminuria and normoalbuminuria, and as a result we cannot rule out
a role for hemolysis in the pathogenesis of albuminuria in SCD. The lower hemoglobin level
in patients with macroalbuminuria may also be due to the decreased renal function and
consequent decreased production of erythropoietin in these patients (30,31).
Multiple recent reports show an association of PHT with laboratory measures of renal
function in patients with SCD (1,2,4). In addition, De Castro and colleagues reported an
association of proteinuria with PHT (4). The reason for this association was previously
uncertain, although it was suspected that both PHT and glomerulopathy in SCD share a
similar pathophysiology. Our present study suggests that the association of albuminuria with
PHT may occur, at least in part, due to the increased endothelial activation and endothelial
dysfunction that follow increased levels of sFLT-1 in these patients. Indeed, we have
recently reported that sFLT-1 is associated with PHT in SCD (19). The observed association
of albuminuria with NT-proBNP, a laboratory marker of cardiac dysfunction and an
established predictor of PHT in SCD (32), appears to provide additional evidence for the
relationship between albuminuria and PHT. However, as NT-proBNP is significantly
cleared by the kidney (33,34), the higher level of NT-proBNP in patients with
macroalbuminuria may also be due to the reduced renal clearance in these patients compared
with those patients with both normoalbuminuria and microalbuminuria.
The association of albuminuria with both PHT and a history of stroke suggest that
albuminuria may be a risk factor for these complications in SCD. Furthermore, as
proteinuria is associated with glomerulopathy (35), our finding highlights the importance of
early screening for albuminuria in SCD patients. However, other studies are required to
determine the natural history of microalbuminuria in SCD. Furthermore, longitudinal studies
are required to determine whether the presence of microalbuminuria is predictive of specific
SCD-associated complications. Treatment with hydroxyurea has been reported to prevent
the development and progression of microalbuminuria in some patients with SCD (14).
Other studies suggest that angiotensin converting enzyme inhibitors may be beneficial in
SCD patients with microalbuminuria (36,37). A randomized, double-blind, placebo-
controlled study of captopril in 22 normotensive HbSS patients showed significant
differences in the mean absolute change (-45 mg per 24 hours in captopril group vs. +18 mg
per 24 hours in the placebo group, P < 0.01) and the mean percentage change (37% in
captopril group vs. +17% in the placebo group, P <0.01) in microalbuminuria between the
two treatment groups at 6 months (36). In addition, a single institution retrospective analysis
reported that the combination of hydroxyurea and enalapril was associated with a near
normal urine protein/creatinine ratio in 3 patients with sickle cell anemia following 3.5 ± 1.2
years of treatment (37). Pharmacologic interventions such as angiotensin converting enzyme
inhibitors, angiotensin receptor blockers and aldosterone antagonists may have anti-
inflammatory properties that are independent of their hemodynamic effect (38) and may
prove to be beneficial in SCD patients with microalbuminuria.
In conclusion, our study confirms the high prevalence of albuminuria in patients with SCD.
Although limited by its exploratory nature, the association of urine albumin excretion with
sFLT-1 suggests that this VEGFR family member may contribute to the development of
albuminuria in SCD. Furthermore, by inducing endothelial activation and endothelial
dysfunction, sFLT-1 appears to be a link between glomerulopathy and PHT in patients with
SCD. Prospective studies are needed to further evaluate the association of albuminuria with
clinical complications of SCD, as well as assess the risk factors for progression of
Ataga et al. Page 6













albuminuria in these patients. Finally, additional studies are needed to determine the role of
sFLT-1 in the pathogenesis of albuminuria in SCD.
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